FindTrial
Sign In

Allogeneic Adenovirus-specific Cytotoxic T Lymphocytes

BIOLOGICAL2 trials

Sponsors

M.D. Anderson Cancer Center, Sumithira Vasu

Conditions

AdenovirusAllogeneic Hematopoietic Stem Cell Transplantation RecipientCytomegalovirusDonorHematopoietic and Lymphoid Cell NeoplasmImmunocompromisedSolid Organ Transplantation Recipient

Early Phase 1

Donor Virus-Specific CMV or AdV CTL to Treat CMV or AdV Reactivation or Disease After Solid Organ or HCT
RecruitingNCT03665675
Sumithira VasuAdenovirus, Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Cytomegalovirus +2
Start: 2020-11-07End: 2026-12-20Target: 20Updated: 2026-04-15

Phase 1

Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
RecruitingNCT03425526
M.D. Anderson Cancer CenterHematopoietic and Lymphoid Cell Neoplasm, Immunocompromised
Start: 2018-03-15End: 2027-01-01Target: 16Updated: 2026-09-04

Related Papers

Off-the-shelf virus specific T-cells for therapy of adenovirus disease in immunosuppressed patients.
Journal of Clinical Oncology2019-05-201 citations